Tiny Human Nerve Models Bring Fresh Hope for Spinal Cord Repair

Scientists at the University of Cambridge have made an encouraging discovery that could brighten the future of nerve repair research. By growing tiny laboratory models of the human brain and spinal cord, the team has shown that some nerve damage once considered permanent may be reversible under the right conditions.

The work offers a hopeful new way to study how movement signals travel through the human nervous system and how those signals might one day be restored after injury.

A Miniature Window Into Human Movement

During early human development, neurons build intricate communication networks linking the brain, spinal cord, and muscles. These messages travel along axons, the long fibers that allow nerve cells to send movement signals through the body.

In adults, however, the central nervous system has only a limited ability to repair these axons after injury. Damage to the brain or spinal cord can therefore lead to lasting disabilities, including paralysis and loss of movement. Reduced nerve regeneration is also connected to conditions such as motor neurone disease and multiple sclerosis.

To better understand this challenge in a human system, researchers at Cambridge created a miniature lab-grown model of the connected brain and spinal cord.

Building on Earlier Organoid Success

In 2021, Dr. András Lakatos and his team developed pea-sized “brain organoids” from patient stem cells. These tiny models resembled parts of the cerebral cortex and helped researchers investigate molecular changes involved in motor neurone disease.

Their latest study, published in Cell Reports, takes that achievement a step further. The researchers built a small-scale version of the human brain-spinal cord connection.

Because the brain and spinal cord are distinct but linked structures in the body, the scientists kept the organoids separate in the lab. They then watched as axons from the brain tissue grew across the space and connected with the spinal cord tissue. The new circuit was active enough to cause contractions in tiny clusters of muscle cells, showing that the model could reproduce key features of movement signaling.

A Crucial Developmental Turning Point

The Cambridge team kept these miniature nervous system models alive in the lab for more than a year. This long-term view allowed them to observe when human neurons begin to lose their natural ability to regrow after damage.

They found that before around day 150 of development, which roughly matches the middle stage of pregnancy, injured axons could still regenerate. After that point, the neurons’ ability to regrow declined sharply.

George Gibbons from the Department of Clinical Neurosciences at the University of Cambridge and first author of the study said: "Neurons taken from less mature organoids regrew long fibers after injury, but those from more mature organoids showed a sharp drop in their ability to regrow. In other words, poor regeneration is built into human neurons as they mature in the central nervous system."

The researchers also studied gene activity in neurons that link the brain and spinal cord. They identified a gene network that appears to work like a biological switch, restricting axon growth as neurons mature and form synapses.

In an especially promising result, blocking important regulators in this network helped neurons recover their ability to grow axons.

An Approved Drug Points to New Possibilities

The team then searched a database of drug compounds to find medicines that could influence the newly discovered gene network. One standout candidate was lynestrenol, a hormone drug already approved for certain menstrual disorders and contraceptive use.

When tested on damaged neurons, lynestrenol significantly improved axon regrowth.

The researchers emphasized that nerve repair is complex. Scar tissue and inflammation can also make recovery difficult after injury. Still, identifying the neuron-specific mechanisms that limit regrowth is an important and optimistic step forward. Earlier evidence has suggested that younger neurons may be able to grow through environments that usually prevent repair.

Senior author Dr. András Lakatos, who led the study at the Department of Clinical Neurosciences, said: "When the brain and spinal cord are damaged, the nerve fibers that carry movement signals from the brain to the spinal cord rarely grow back. That's why paralysis is usually permanent. But we didn't know exactly when the ability of axons to regenerate becomes limited. Our model provides a good indication that this block happens during development, and it can still be reversed after this point.

"Lynestrenol itself may not be the answer to spinal cord repair, but it shows us that, in principle, it should be possible to directly target human neurons and regenerate their axons. Although we still need to show that this strategy will also help to re-establish appropriate connections between the brain and spinal cord cells, this gives us hope that one day we may be able to treat conditions previously thought untreatable."

Why Human Organoids Are So Valuable

Organoids are becoming powerful tools for exploring human biology with greater accuracy. Animal models such as mice and rats remain important in science, but human neurons can behave differently from rodent neurons. This means that discoveries in animals do not always translate directly to patients.

Human stem cell-derived organoids help close that gap. They allow scientists to study disease and repair in systems that more closely resemble human biology.

Dr. Lakatos added: "Much of what we know about nerve regeneration comes from rodents, whose neurons behave differently from human neurons. Our sophisticated organoid models help bridge the knowledge gap from animal models to what we see in patients. They are also an important contribution to efforts to reduce the use of animals in research."

A Hopeful Path for Future Medicine

The Cambridge research adds to a growing wave of organoid-based medical studies. Scientists at the university are already using organoids to investigate ways to repair damaged livers, study Crohn’s disease in children, and explore the earliest stages of pregnancy.

This latest work brings a particularly hopeful message: even when nerve regrowth seems to be switched off during development, that block may not be absolute. With further research, the discovery could help guide future treatments for injuries and diseases once thought impossible to repair.

The study was funded by the UK Research and Innovation Medical Research Council and Spinal Research.